Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine in what way infections, microbiome, and vaccinations during childhood interact in shaping the development of immunity and tolerance. The investigators collect and use data from a birth cohort focusing on infectious diseases during childhood and apply a life course perspective.


Clinical Trial Description

The goal of the study is to capture the complete history of exposure towards microbial challenges in the first six years of life and to study interactions between different components of microbial exposure as well as effects on the development of immunity. The investigators apply a diary in which parents document symptoms of respiratory and gastrointestinal infections of their child, and collect nasal swabs and stool samples obtained on first day of symptoms. In addition, the investigators collect nasal swabs and stool samples once per year during an asymptomatic period. The investigators intend to collect venous blood from children participating in the study at the age of six years. In a subsample (called intensive subcohort), the investigators collect asymptomatic probes three monthly during the first two years of life and obtain venous blood of the children at the age of one and two years. The study sample is 782 participants, with 285 participants in the intensive subcohort. Symptomatic samples will be analyzed by means of multiplex polymerase chain reaction (PCR). In addition, the investigators will assess microbial compositions based on next generation sequencing and apply multiplex panels to study parameters of unspecific humoral immune response. The study will allow to assess homologous and heterologous effects of infections and vaccinations measuring specific humoral immune response. In collaboration with immunologists, immune phenotypes will be studied and functional tests will be conducted. The investigators will use allergic dermatitis at the age of two as a primary proxy outcome and target asthma at the age of six years as a definitive clinical endpoint. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02654210
Study type Observational
Source Helmholtz Centre for Infection Research
Contact
Status Active, not recruiting
Phase
Start date March 2015
Completion date February 2033

See also
  Status Clinical Trial Phase
Completed NCT02763345 - The Added Value of a Mobile Application of Community Case Management on Pediatric Referral Rates in Malawi N/A
Completed NCT00550706 - Drug Utilization Prevalence in a Pediatric Care Medical Center N/A
Completed NCT01033799 - Effect of the Consumption of a Fermented Milk on Common Infections in Shift-workers N/A
Completed NCT00761462 - BAY 0 9867 Cipro Pediatric Use Study (QUIP) Phase 3
Completed NCT05088421 - A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of BWC0977 in Healthy Volunteers Phase 1
Completed NCT00828971 - A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs Phase 3
Completed NCT05468723 - Evaluating Patient Comfort and Environmental Conditions in the Carecube Negative Pressure Isolation Chamber.1
Recruiting NCT02162966 - Safety and Efficacy Study of High Dose Colistin Phase 4
Recruiting NCT00001281 - Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIV
Completed NCT02226263 - Severe Necrotizing Enterocolitis in Preterm Newborns <1500g Using Probiotics Phase 2
Terminated NCT00211471 - Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.). Phase 2
Active, not recruiting NCT04342702 - A Study on the Prospective Cohort Library of COVID-19 in Southeran
Completed NCT02134548 - Sensitivity Study of Diagnostic for Detection of Chagas Infection N/A
Active, not recruiting NCT01611025 - Hospital Microbial Ecology Follow the Introduction of Ertapenem and Other Newly Introduced Antibiotic Over Time N/A
Completed NCT01361997 - Isopropyl Alcohol Against Chlorhexidine - Isopropyl Alcohol as Antiseptics to Prevent Hemoculture's Contamination Phase 3
Completed NCT00638677 - Bifidobacterium Lactis BB12 and Xylitol Delivered With a Novel Slow-release Pacifier Phase 4
Completed NCT02434848 - A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses Phase 2/Phase 3
Completed NCT02544139 - Specificity Study of Diagnostic for Chagas Disease N/A
Completed NCT00276198 - Efficacy Trial to Examine Efficacy of Multimicronutrient Home Supplementation in Infants Phase 3
Completed NCT02111564 - A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients Phase 3